Israeli pharmaceutical company Kamada has announced that it has received FDA approval for a phase II and III clinical trial of AATD-IH, an inhalable version of its AAT drug, which is designed to treat congenital emphysema.
Related posts
Israeli Cybersecurity Startup To Provide Training For IDF
October 10, 2024
Johnson & Johnson Completes Purchase Of Israeli Startup V-Wave
October 10, 2024
Weizmann Researchers Create Biodegradable Composite Plastic
October 09, 2024
IIA Funds Further Israeli R&D Into Crustacean Gene Modification
October 09, 2024
Facebook comments